This Magnificent High-Yield Dividend Stock Just Became an Even Better Buy
Medical device specialist Medtronic (NYSE: MDT) has not performed well over the past five years; the stock has significantly lagged broader equities. One of the issues it's encountered is slow revenue growth. Although it explored plans to spin off some of its low-growth units to improve on that front, it eventually abandoned the idea.However, new developments suggest that Medtronic could soon tap into a significant long-term opportunity. Let's look deeper into that and discuss what it means for investors.Medtronic has been developing its robotic-assisted surgery (RAS) device, the Hugo system, for years. The machine is in use in many countries, but it hasn't been cleared in the U.S. yet. That's where Medtronic could make the most money, though, so the company has been testing its Hugo system in the U.S. to support regulatory clearance.Continue reading
Medical device specialist Medtronic (NYSE: MDT) has not performed well over the past five years; the stock has significantly lagged broader equities. One of the issues it's encountered is slow revenue growth. Although it explored plans to spin off some of its low-growth units to improve on that front, it eventually abandoned the idea.
However, new developments suggest that Medtronic could soon tap into a significant long-term opportunity. Let's look deeper into that and discuss what it means for investors.
Medtronic has been developing its robotic-assisted surgery (RAS) device, the Hugo system, for years. The machine is in use in many countries, but it hasn't been cleared in the U.S. yet. That's where Medtronic could make the most money, though, so the company has been testing its Hugo system in the U.S. to support regulatory clearance.
